**CapsoVision, Inc. Reports Financial Results and Strategic Updates in 10-K Filing**
CapsoVision, Inc., a medical technology company focused on GI tract diagnostics, reported its financial results in its recent 10-K filing, revealing a revenue increase of 15% for the year ended December 31, 2025, reaching $13.6 million compared to $11.8 million in 2024. This growth was primarily driven by increased sales of the company's CapsoCam Plus capsule, which has been used in over 161,000 patients as of the end of 2025. Despite the revenue growth, the company reported a net loss of $25.3 million for 2025, compared to a net loss of $19.9 million in the previous year, contributing to an accumulated deficit of $155.7 million. The company's international sales accounted for 21% of total revenue in 2025, slightly down from 23% in 2024.
The filing also highlighted strategic developments, including the company's focus on obtaining FDA clearance for its second-generation CapsoCam Colon capsule, featuring improved imaging quality and AI capabilities. CapsoVision expects to submit the 510(k) application for this product in the third quarter of 2026. The company has decided not to further pursue the first generation CapsoCam Colon capsule submission and approval, and to prioritize its resources for the development of its second generation CapsoCam Colon capsule. As of the date of the report, over 500 patients have been enrolled for the second arm pivotal study. The company is also working on incorporating AI into its CapsoCam Plus capsule, with FDA clearance targeted for mid-2026.
Operationally, CapsoVision reported a customer retention rate of approximately 90% for 2025. The company's sales efforts are divided into two groups, one focused on the U.S. market and the other on international markets, with international sales primarily conducted through qualified distributors. As of December 31, 2025, CapsoVision had 28 full-time sales employees in the U.S., including 4 sales directors and 23 territory managers. The company is also developing a capsule delivery device, expected to be fully commercialized in the fourth quarter of 2026, and a patency capsule, with a tentative FDA 510(k) submission planned by the end of the second quarter of 2026. The company's research and development expenses increased to $18.3 million in 2025 from $15.1 million in 2024. As of December 31, 2025, the company had approximately 99 full-time employees.
The 10-K filing also included forward-looking statements regarding the company's expectations for product acceptance, market size, FDA clearances, and future financial performance. However, the company cautioned that these statements are subject to risks and uncertainties, including the company's history of net losses, the need for additional financing, and the competitive landscape. The company's audited financial statements for 2025 and 2024 include a footnote raising substantial doubt about its ability to continue as a going concern. The company held over 140 issued patents as of December 31, 2025, covering various aspects of its capsule and technology.
About CapsoVision, Inc
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.